Elsevier

Clinical Therapeutics

Volume 24, Issue 11, November 2002, Pages 1770-1785
Clinical Therapeutics

A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia

https://doi.org/10.1016/S0149-2918(02)80078-9Get rights and content

Abstract

Background: Ertapenem is a once-daily parenteral beta-lactam licensed in the United States in November 2001 and in Europe in May 2002.

Objective: This study compared the efficacy and safety profiles of ertapenem with those of ceftriaxone for the treatment of hospitalized adult patients with serious community-acquired pneumonia (CAP) requiring parenteral therapy.

Methods: In this prospective, double-blind (with sponsor blinding), multicenter study, adult patients with CAP were stratified by Pneumonia Severity Index (≤3 or >3) and age (≤65 or >65 years) and randomized (2:1) to receive IV or intramuscular (IM) ertapenem 1 g once daily or IV or IM ceftriaxone 1 g once daily. Investigators could switch patients to an oral antimicrobial agent if clinical improvement was shown after at least 3 days of parenteral therapy.

Results: A total of 364 patients were randomized to treatment: 239 to the ertapenem group and 125 to the ceftriaxone group. Three patients in the ertapenem group and 2 in the ceftriaxone group did not receive study therapy. Of the treated patients, 77.1% (182/236) of patients in the ertapenem group and 75.6% (93/123) in the ceftriaxone group were clinically evaluable. Among clinically evaluable patients, the mean (SD) durations of parenteral and total (parenteral plus optional oral) therapy were 5.5 (2.6) and 11.5 (2.7) days for ertapenem and 5.6 (2.8) and 11.7 (3.0) days for ceftriaxone, respectively. Streptoccocus pneumoniae was the most frequently isolated pathogen in both treatment groups. Cure rates were 92.2% for clinically evaluable patients in the ertapenem group and 93.6% for those in the ceftriaxone group (95% CI for the difference, adjusted for stratum, −8.6 to 5.7), fulfilling the criteria for statistical equivalence. At completion of parenteral therapy, 94.7% of patients in the ertapenem group and 95.8% in the ceftriaxone group showed clinical improvement. Infused vein complications (ertapenem, 3.4% [8/236]; ceftriaxone, 7.3% [9/123]) and elevated transaminase levels (ertapenem, 6.3% [13/207]; ceftriaxone, 7.1% [8/113]) were the most common adverse events in both groups.

Conclusions: In this study of hospitalized adult patients, ertapenem therapy, with an oral switch option, was as effective as ceftriaxone with the same oral switch option for treatment of CAP requiring initial parenteral therapy. The overall safety profiles of the 2 drugs were comparable.

References (24)

  • S Moola et al.

    A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia

    Chest

    (1999)
  • C Feldman

    Pneumonia in the elderly

    Med Clin North Am

    (2001)
  • Introduction to Table V. Premature deaths, monthly mortality and monthly physician contacts—United States

    MMWR Morb Mortal Wkly Rep

    (1997)
  • BJ Marston et al.

    Results of a population-based active surveillance study in Ohio

  • JF Guest et al.

    Community-acquired pneumonia: The annual cost to the National Health Service in the UK

    Eur Respir J

    (1997)
  • MJ Fine et al.

    A prediction rule to identify low-risk patients with community-acquired pneumonia

    N Engl J Med

    (1997)
  • DM Livermore et al.

    In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

    Antimicrob Agents Chemother

    (2001)
  • PC Fuchs et al.

    In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers

    Antimicrob Agents Chemother

    (2001)
  • P Zuck et al.

    Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia

    J Antimicrob Chemother

    (1990)
  • RE McCabe et al.

    Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease

    Clin Ther

    (1989)
  • A Segev et al.

    Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections

    Eur J Clin Microbiol Infect Dis

    (1995)
  • SL Phillips et al.

    The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia

    J Am Geriatr Soc

    (1993)
  • Cited by (72)

    • Higher than expected rates of seizures associated with the use of ertapenem in older hospitalized patients

      2013, Journal of Clinical Gerontology and Geriatrics
      Citation Excerpt :

      Of these, 14 are randomized controlled trials with active comparator arms, while two included open-label experiences in treating ventilator-associated pneumonia.28,29 Of the nearly 3000 patients who received a single dose of 1 g or more of ertapenem, only three drug-related seizures were reported.16,21,22 Several other case reports show an incidence rate of up to 0.5% in adults.30–35

    • Guidelines for the management of adult lower respiratory tract infections - Summary

      2011, Clinical Microbiology and Infection
      Citation Excerpt :

      Penicillin G ± macrolide dIn patients at risk of gram-negative enteric bacterium, particularly strains with extended-spectrum β-lactamase, but without risk (or after exclusion) of P. aeruginosa, ertapenem may be used [100,158,274–304]. Treatment options for patients with severe community-acquired pneumonia [C4] (ICU or intermediate care).

    View all citing articles on Scopus

    Members of the Protocol 020 Study Group are listed in the Acknowledgments.

    View full text